These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 38920278)
21. The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer. Lee AM; Saidian A; Shaya J; Nonato T; Cabal A; Randall JM; Millard F; Stewart T; Rose B; Tamayo P; McKay RR Clin Genitourin Cancer; 2022 Dec; 20(6):515-523. PubMed ID: 35871039 [TBL] [Abstract][Full Text] [Related]
22. Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world. Lu Y; Jiang J; Yang G; Ding H; Zheng Q; Ji L; Wang Y; Dong Z; Zhai Z; Tian J; Zhang Y; Wang J; Yang L; Wang Z Front Oncol; 2024; 14():1324181. PubMed ID: 38699643 [TBL] [Abstract][Full Text] [Related]
23. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623 [TBL] [Abstract][Full Text] [Related]
24. The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Iannantuono GM; Torino F; Rosenfeld R; Guerriero S; Carlucci M; Sganga S; Capotondi B; Riondino S; Roselli M Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955671 [TBL] [Abstract][Full Text] [Related]
26. KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer. Graff JN; Liang LW; Kim J; Stenzl A Future Oncol; 2021 Aug; 17(23):3017-3026. PubMed ID: 34044584 [TBL] [Abstract][Full Text] [Related]
27. Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents. Hafron JM; Wilfehrt HM; Ferro C; Harmon M; Flanders SC; McKay RR Adv Ther; 2022 Jun; 39(6):2515-2532. PubMed ID: 35352309 [TBL] [Abstract][Full Text] [Related]
28. Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone. Sheng IY; Fallah J; Gupta R; Li H; Allman K; Martin A; Barata P; Ornstein MC; Gilligan TD; Rini BI; Garcia JA Target Oncol; 2020 Aug; 15(4):477-483. PubMed ID: 32661959 [TBL] [Abstract][Full Text] [Related]
30. KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. Petrylak DP; Ratta R; Gafanov R; Facchini G; Piulats JM; Kramer G; Flaig TW; Chandana SR; Li B; Burgents J; Fizazi K Future Oncol; 2021 Sep; 17(25):3291-3299. PubMed ID: 34098744 [TBL] [Abstract][Full Text] [Related]
31. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187 [TBL] [Abstract][Full Text] [Related]
32. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. Annala M; Struss WJ; Warner EW; Beja K; Vandekerkhove G; Wong A; Khalaf D; Seppälä IL; So A; Lo G; Aggarwal R; Small EJ; Nykter M; Gleave ME; Chi KN; Wyatt AW Eur Urol; 2017 Jul; 72(1):34-42. PubMed ID: 28259476 [TBL] [Abstract][Full Text] [Related]
33. Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting. Sayegh N; Tripathi N; Nussenzveig RH; Thomas VM; Tandar C; Goel D; Nordblad B; Sahu KK; Li H; L Maughan B; Agarwal N; Swami U Eur Urol Focus; 2023 Jan; 9(1):106-109. PubMed ID: 35835693 [TBL] [Abstract][Full Text] [Related]
34. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683 [TBL] [Abstract][Full Text] [Related]
35. [New treatment approaches for and ongoing trials in metastatic hormone-sensitive prostate cancer]. Isgandarov A; Darr C; Posdzich P; Hermann K; Hadaschik BA; Grünwald V Urologie; 2023 Apr; 62(4):369-375. PubMed ID: 36823372 [TBL] [Abstract][Full Text] [Related]
36. Germline Variant in Hahn AW; Gill DM; Poole A; Nussenzveig RH; Wilson S; Farnham JM; Stephenson RA; Cannon-Albright LA; Maughan BL; Agarwal N Mol Cancer Ther; 2019 Mar; 18(3):726-729. PubMed ID: 30587554 [TBL] [Abstract][Full Text] [Related]